Sage Journals: Discover world-class research

Abstract

Objective

The objective of this paper is to evaluate the performance of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) in detecting clinically meaningful changes in SLE disease activity.

Methods

A longitudinal cohort study was conducted of 334 SLE patients during a 36-month follow-up. At each outpatient visit, disease activity was scored using the Physician Global Assessment (PGA) and SLEDAI-2K. Correlations between PGA and SLEDAI-2K were assessed. A clinically meaningful change in SLE disease activity was defined as a ΔPGA ≥ 0.3 points from baseline. Performance of SLEDAI-2K in detecting a clinically meaningful worsening or improvement was tested using receiver operating characteristic (ROC) analysis.

Results

Adjusted mean PGA and SLEDAI-2K scores presented a high correlation (rho = 0.824, p < 0.0005). In ROC analysis, a SLEDAI-2K variation presented an area under the curve (AUC) of 0.697 (95% confidence interval (CI) (0.628–0.766), p < 0.0005) to detect a clinically meaningful improvement, with a sensitivity of 28.8% for a SLEDAI-2K ≥ 4 reduction. The AUC to detect a clinically meaningful worsening was 0.877 (95% CI (0.822–0.932), p < 0.0005), with a sensitivity of 35.3%.

Conclusions

SLEDAI-2K has a limited ability to detect clinically meaningful changes in SLE disease activity, failing to identify almost two-thirds of cases judged as having a clinically meaningful improvement or worsening. There is a need for more sensitive SLE disease activity measures in clinical practice and research.

Keywords

Disease activity index systemic lupus erythematosus SLEDAI SRI

Get full access to this article

View all access options for this article.

References

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

Gladman

Ibañez

Urowitz

. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288–291.

Petri

Kim

Kalunian

et al.

Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

Furie

Petri

Wallace

et al.

Novel evidence-based Systemic Lupus Erythematosus Responder Index. Arthritis Rheum 2009; 61: 1143–1151.

van Vollenhoven

Voskuyl

Bertsias

et al.

A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554–561.

Franklyn

Lau

Navarra

et al.

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615–1621.

Zen

Iaccarino

Gatto

et al.

Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis 2015; 74: 2117–2122.

Kalunian

Urowitz

Isenberg

et al.

Clinical trial parameters that influence outcomes in lupus trials that use the Systemic Lupus Erythematosus Responder Index. Rheumatology (Oxford) 2018; 57: 125–133.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

10.

Petri

Orbai

Alarcón

et al.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

11.

Ibañez

Urowitz

Gladman

. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003; 30: 1977–1982.

12.

R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2010.

13.

Fatemi

Raeisi

Sayedbonakdar

Smiley

. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: A longitudinal study. Clin Rheumatol 2018; 37: 955–962.

14.

Uribe

Vilá

McGwin

Jr Sanchez

Reveille

Alarcón

. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004; 31: 1934–1940.

15.

Ward

Marx

Barry

. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000; 27: 664–670.

16.

Gladman

Goldsmith

Urowitz

et al.

Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: International validation. J Rheumatol 1994; 21: 1468–1471.

17.

Yee

Isenberg

Prabu

et al.

BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 2008; 67: 873–876.

18.

Chang

Abrahamowicz

Ferland

Fortin

. CaNIOS Investigators. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidemiol 2002; 55: 488–497.

19.

Fortin

Abrahamowicz

Clarke

et al.

Do lupus disease activity measures detect clinically important change?

J Rheumatol 2000; 27: 1421–1428.

20.

Devilliers

Bonithon-Kopp

Jolly

. The Lupus Impact Tracker is responsive to changes in clinical activity measured by the Systemic Lupus Erythematosus Responder Index. Lupus 2017; 26: 396–402.

21.

Jesus

Matos

Henriques

et al.

Derivation and validation of the SLE Disease Activity Score (SLE-DAS): A new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 2019; 78: 365–371.

22.

Hahn

McMahon

Wilkinson

et al.

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797–808.

23.

Askanase

Pong

et al.

Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): An efficient outcome measure correlates with validated instruments. Lupus Sci Med 2015; 2: e000075–e000075.

24.

Touma

Gladman

Ibañez

Urowitz

. Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. J Rheumatol 2011; 38: 275–284.

25.

Touma

Gladman

Ibañez

Taghavi-Zadeh

Urowitz

. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol 2011; 38: 2395–2399.

26.

Touma

Gladman

Ibañez

Urowitz

. SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years. Lupus 2012; 21: 1305–1311.

27.

Touma

Urowitz

Fortin

et al.

Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: A reliable index for measuring improvement in disease activity. J Rheumatol 2011; 38: 868–873.

28.

Touma

Urowitz

Taghavi-Zadeh

Ibañez

Gladman

. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: Sensitivity to response at 6 and 12 months. Rheumatology (Oxford) 2012; 51: 1814–1819.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.12 MB

Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36–month prospective cohort study of 334 patients

Abstract

Objective

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material